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The 22q11.2 deletion syndrome (22q11DS) is characterized by high rates of psychotic symptoms 
and schizophrenia, making this condition a promising human model for studying risk factors for 
psychosis. We explored the predictive value of ultra high risk (UHR) criteria in a sample of patients 
with 22q11DS. We also examined the additional contribution of socio-demographic, clinical and 
cognitive variables to predict transition to psychosis within an interval of 32.5±17.6 months after 
initial assessment. Eighty-nine participants with 22q11DS (age range: 8-30 years; mean 16.1±4.7) 
were assessed using the Structured Interview for Psychosis-Risk Syndromes. Information on Axis I 
diagnoses, internalizing and externalizing symptoms, level of functioning and IQ was also 
collected. At baseline, 22 (24.7%) participants met UHR criteria. Compared to those without a UHR 
condition, they had a significantly lower functioning, more frequent anxiety disorders, and more 
severe psychopathology. Transition rate to psychosis was 27.3% in UHR and 4.5% in non-UHR 
participants. Cox regression analyses revealed that UHR status significantly predicted conversion 
to psychosis. Baseline level of functioning was the only other additional predictor. This is the first 
study investigating the predictive value of UHR criteria in 22q11DS. It indicates that the clinical 
path leading to psychosis is broadly comparable to that observed in other clinical high-risk 
samples. Nevertheless, the relatively high transition rate in non-UHR individuals suggests that 
other risk markers should be explored in this population. The role of low functioning as a predictor 
of transition to psychosis should also be investigated more in depth. 
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In the past 20 years, there has been an increasing interest in people presenting with 
potentially prodromal symptoms of psychosis, i.e. with a clinical high risk state. Criteria have been 
developed to identify that high risk state: the ultra high risk (UHR) and the basic symptom 
criteria1,2. A recent meta-analysis reported an ability of UHR criteria to detect transition to 
psychosis within two years in 20% of individuals in clinical samples3. Yet, although persons with a 
clinical high risk state have a significantly increased risk of developing psychosis, many will not 
develop a psychotic disorder. The specificity of clinical high risk assessments hence remains 
relatively low4. 
Studies of genetic syndromes associated with increased risk of schizophrenia have become 
increasingly important. Among these genetic conditions, 22q11.2 deletion syndrome (22q11DS) is 
particularly valuable5. This syndrome is characterized in most cases by a microdeletion of 3 million 
base pairs on chromosome 22 band q11, and has an estimated prevalence of 1:2.000-4.000 live 
births6. From a clinical perspective, 22q11DS is associated with high rates of psychiatric disorders, 
especially schizophrenia7. While 23 to 45% of adolescents report transient psychotic experiences8-
11, up to 40% of affected adults are diagnosed with a psychotic disorder7. Moreover, 22q11DS was 
found in 0.3 to 2.0% of patients with schizophrenia12-14, with rates of up to 5.7% in patients with 
childhood-onset schizophrenia15. Taken together, these findings indicate that 22q11DS is a highly 
relevant genetic risk factor for schizophrenia and the most promising human model for studying 
risk factors and states at risk for schizophrenia5.  
Several studies have investigated prodromal symptoms in patients with 22q11DS, reporting 
rates between 45 and 56% for UHR symptoms and between 10 and 21% for UHR criteria 
(including frequency and onset/worsening requirements)8,10,11,16-18. Armando et al8 compared the 
symptom profile of UHR patients with (N=30) vs. without (N=81) 22q11DS and found no significant 
group difference in positive symptoms, while negative symptoms were more severe in patients with 
22q11DS. 
Yet, few studies have prospectively investigated risk factors for psychosis in the 22q11DS 
population. Gothelf et al19 found that anxiety disorder and lower full-scale IQ at baseline, and a 
greater decline in verbal IQ were the best predictors of transition to psychosis. In line with these 
findings, Vorstman et al20 reported that an early cognitive decline, particularly in verbal IQ, was a 
robust predictor of psychosis. Finally, a recent study highlighted the role of poor premorbid 
adjustment during childhood and adolescence in the development of UHR symptoms and full-
blown psychosis21. No study, however, has longitudinally examined the predictive value of UHR 
criteria in people with 22q11DS. 
We investigated prospectively, in a large group of patients with 22q11DS over an average 
period of 32 months, the predictive value of UHR criteria as well as potential other predictors of 
conversion to psychosis. We hypothesized that the predictive value of UHR criteria would be 
comparable to that found in other clinical samples, albeit expecting an overall higher transition rate, 
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given the higher prevalence of psychotic disorders in 22q11DS. Secondly, we expected that low 
baseline verbal IQ, the presence of an anxiety disorder, and low baseline level of functioning would 
increase the predictive accuracy in addition to the presence of an UHR condition. 
 
 
METHODS 
 
Participants 
 
We included 89 participants (56 from Geneva and 33 from Rome) with a genetically confirmed 
22q11DS diagnosis, aged between 8 and 30 years (mean 16.1±4.7) at baseline. Having a 
psychotic disorder at baseline was an exclusion criterion. Children were assessed from the age of 
8 onwards, as previous studies reported the presence of psychotic symptoms in young children 
with 22q11DS9. Participants were followed-up over a mean period of 32.5±17.6 months (range: 12-
85).  
Participants from Geneva were recruited through advertisements in patient associations or 
word of mouth; those from Rome were referred from the Genetic Clinical Unit of the Bambino Gesù 
Hospital or recruited through advertisement in patient associations. Written informed consent from 
the participants and their parents was collected at both sites under protocols approved by local 
institutional ethical review boards. 
Compared to the Geneva cohort, participants from Rome were younger (mean age 14.3±5.1 
vs. 17.1±4.2 years, t=2.89, p=0.005) and had a higher full-scale IQ (84.5±10.9 vs. 72.2±10.0, 
t=5.44, p<0.001), while the gender distribution at baseline was similar (females: 51.5% vs. 55.4%, 
2=0.12, p=0.725). 
 
Assessments 
 
All participants completed the Structured Interview for Psychosis-Risk Syndromes22 to assess 
the severity of positive, negative, disorganization and general symptoms, as well as the presence 
of UHR symptoms (any P1-P5 3) and UHR criteria (i.e., attenuated psychotic symptoms (APS), 
brief limited intermittent symptoms (BLIPS), or genetic risk and functional decline (GRFD) criteria). 
We also explored the rate of participants meeting criteria for perceptive (P4) and non-perceptive 
(P1, P2, P3 or P5) APS or BLIPS23. For the global assessment of functioning, the Childhood 
Global Assessment Scale (CGAS)24 or the Global Assessment of Functioning (GAF) was used. 
The presence of any Axis I DSM-IV psychiatric disorder was assessed using structured clinical 
interviews. In both cohorts, the Structured Clinical Interview for Axis I DSM-IV (SCID-I)25 was 
administered to adult participants and their parents. In Geneva, parents of participants below 18 
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years completed the Diagnostic Interview for Children and Adolescents - Revised (DICA-IV)26 and 
diagnoses were confirmed with the participants. The psychotic disorders supplement of the 
Schedule for Affective Disorders and Schizophrenia for School-Age Children - Present and 
Lifetime version (K-SADS-PL)27 was also administered. In Rome, the K-SADS-PL, including the 
psychotic disorders supplement, was used for children and adolescents. 
Intellectual functioning was assessed by trained psychologists at both time points using the 
Wechsler Intelligence Scale for Children - third edition (WISC-III)28 or the Wechsler Adult 
Intelligence Scale - third edition (WAIS-III)29. Verbal IQ, performance IQ and full-scale IQ were 
used as indicators of intellectual functioning. 
Parents of all participants completed the Child Behavior Checklist (CBCL)30 or the Adult 
Behavior Checklist (ABCL)31. Internalizing, externalizing and total problems T-scores were used as 
global measures of the severity of psychopathology.  
 
Statistical analyses 
 
All statistical analyses were performed using SPSS version 21. Cross-sectional group 
comparisons between participants with and without UHR criteria at baseline were performed using 
independent t-tests, Mann-Whitney U, or 2 tests. Because of the variable interval between 
baseline and follow-up, we conducted a Cox regression analysis to determine whether the 
presence of any UHR state at baseline (UHR status) significantly predicted conversion to 
psychosis. Furthermore, we used Cox regression analyses to examine whether perceptive and 
non-perceptive APS/BLIPS were both predictors of conversion to psychosis. In case of two 
significant models, both predictors were entered in a stepwise Cox regression analysis. 
We then examined the contribution of additional variables at baseline to improve the UHR-
based prediction model. Potential predictors included: demographic characteristics (age, gender), 
clinical parameters (presence of any anxiety, affective or behavioral disorder, CGAS/GAF scores, 
CBCL/ABCL internalizing, externalizing and total problems T-scores, and severity of positive, 
negative, disorganization and general symptoms), and cognitive variables (verbal, performance 
and full-scale IQ). 
A multiple step approach was adopted in order to derive a parsimonious model. First, each 
predictor was entered individually in a series of Cox regression analyses and selected for further 
analyses when the Wald statistic was significant at a liberal level (p<0.05). Next, each selected 
predictor was entered in a multiple Cox regression analysis, with UHR status always included as a 
predictor. Variables were further selected if the Wald statistic was significant (p<0.05) for both 
variables (UHR status and the additional predictor), indicating that the additional predictor 
contributed to the improvement of prediction without decreasing the predictive value of UHR 
status. If more than one predictor met the above-mentioned criteria, all predictors were analyzed 
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together using a forward and backward Cox regression analysis to exclude effects of blocking. The 
maximum number of predictors entering the final model was limited to a 1:5 ratio of number of 
predictors to event. The proportional hazard assumption was tested at each step prior to each Cox 
regression following the procedure described by Kleinbaum and Klein32. 
 
 
RESULTS 
 
Baseline characteristics 
 
Twenty-two (24.7%) participants met UHR criteria at baseline (UHR+) and 67 (75.3%) did not 
(UHR). Compared to UHR participants, UHR+ were more frequently under antipsychotic 
medication and diagnosed with an anxiety disorder, had more severe positive symptoms (all P 
subscales except grandiosity) and internalizing and externalizing symptoms, and had a lower 
functioning at baseline, although not a higher rate of functional deficit (CGAS/GAF score <70) 
(Table 1). The most frequent UHR condition was APS (N=15; 68.2%), followed by GRFD (N=6; 
27.3%) and BLIPS (N=2; 9.1%); only one participant (4.2%) met criteria for both APS and GRFD. 
Among the 17 participants with APS or BLIPS, four (23.5%) presented with perceptive, six (35.3%) 
with non-perceptive, and seven (41.2%) with both perceptive and non-perceptive APS/BLIPS. 
In addition, 10 (11.2%) participants experienced UHR symptoms  six on item P4 (perceptual 
abnormalities/hallucinations), two on item P2 (suspiciousness/persecutory ideas), and two on 
several items  but failed to meet frequency (N=6) or both frequency and onset/worsening 
requirements (N=4). Altogether, the prevalence of UHR symptoms (regardless of frequency and 
onset/worsening requirements) was 36.0%. 
 
Outcome 
 
Altogether, nine (10.1%) participants had converted to psychosis at follow-up, four being 
minors (<18 years) and five adults at baseline (Table 2). The six UHR+ converters included three 
of those diagnosed with APS (out of 15, 20.0%), both of those diagnosed with BLIPS (100%), and 
one of those diagnosed with GRFD (out of six, 16.7%). Of the three false-negative cases (i.e., 
UHR participants at baseline who converted to psychosis), one had reported UHR symptoms at 
baseline which did not meet frequency and worsening/onset criteria. Five participants (all UHR+) 
were receiving antipsychotic medication at baseline; three of them converted to psychosis at 
follow-up. 
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None of the ten participants who remitted from UHR status (i.e., UHR+ at baseline, but UHR 
at follow-up) had received antipsychotic medication at either baseline or follow-up. Furthermore, 
four (4.5%) participants had a new onset of UHR criteria at follow-up. 
 
Predictors of conversion to psychosis 
 
UHR status at baseline was a significant predictor of transition to psychosis (β=1.823, 
SE=0.733, Wald (df=1) = 6.181, p=0.013; Exp(β) = 6.188, 95% CI: 1.471-26.033). Furthermore, 
presence of both perceptive APS/BLIPS (β=1.644, SE=0.737, Wald (df=1) = 4.975, p=0.026; 
Exp(β) = 5.178, 95% CI: 1.221-21.961) and non-perceptive APS/BLIPS (β=3.397, SE=0.876, Wald 
(df=1) = 15.021, p<0.001; Exp(β) = 29.868, 95% CI: 5.360-166.432) significantly predicted 
transition to psychosis. When both variables were entered in a stepwise Cox regression analysis, 
only the presence of non-perceptive APS/BLIPS remained in the final model. 
With regard to additional predictors, CGAS/GAF at baseline remained the only significant 
predictor after the two selection steps. The final model (Table 3), including UHR status and 
CGAS/GAF as predictors, was highly significant (-2LL=48.768, 2(df=2) = 15.329, p<0.001). 
Cumulative hazard rates of the model were 0.015 at two years, 0.024 at three years and 0.113 at 
four years. 
 
 
DISCUSSION 
 
UHR symptoms and criteria 
 
Altogether, 32 (36.0%) participants reported at least one UHR symptom (APS or BLIPS) 
regardless of the frequency and onset/worsening requirements. Twenty-two of them (24.7%) fully 
met UHR criteria (i.e., including frequency and onset/worsening requirements). Both rates are 
broadly consistent with previous studies in 22q11DS, reporting rates between 45 and 56% for UHR 
symptoms and between 10 and 21% for UHR criteria10,11,16-18,33. Thus, our findings confirm that 
patients with 22q11DS are at increased risk of experiencing attenuated symptoms of psychosis, 
regardless of transition to psychosis23,34. Indeed, recent estimates from the general population 
were between 7.3 and 9.9% for lifetime UHR symptoms and between 0.4 and 1.3% for current 
UHR criteria. 
In the present sample, APS was the most prevalent UHR condition (68.2%), followed by GRD 
(27.3%) and BLIPS (9.1%). While the preponderance of APS and the low frequency of BLIPS is 
consistent with findings from other clinical high risk populations3,35-37, GRFD was more frequent 
than in most clinical UHR samples3. 
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In line with earlier findings9, patients meeting UHR criteria exhibited lower level of functioning 
and higher levels of internalizing and externalizing symptoms, and were more frequently diagnosed 
with an anxiety disorder. These findings highlight that the presence of a UHR status in 22q11DS, 
similarly to other clinical populations3, is in itself a condition that aggravates the clinical picture and, 
consequently, requires clinical attention, irrespective of any potential future transition to psychosis. 
Although a European guidance on early intervention in clinical high risk states does not 
recommend the use of antipsychotics as first line treatment in patients with UHR38, nearly a quarter 
of UHR+ but none of UHR participants were receiving antipsychotic medication at baseline. This 
practice might have been linked to the treating clinicians’ awareness of UHR symptoms and 
increased risk of psychosis in this population, and could be interpreted as a psychosis-prevention 
approach. However, antipsychotics might have been also prescribed for other behavioral 
problems, such as severe anxiety or externalizing symptoms, in this more symptomatic group. 
 
Outcome 
 
We observed a transition rate to psychosis of 27.3% among UHR+ participants, which is 
comparable to previous reports in other clinical samples3,39. Furthermore, with only 4.5% of UHR 
participants developing psychosis, we found that the UHR status significantly predicted transition 
to psychosis in this specific subgroup of patients. However, in light of the increased risk of 
psychosis recognized in this population, it might be surprising that the transition rates were “only” 
in line with those of other clinical samples and not considerably higher40. 
Several reasons may explain this finding. First, the mean age of UHR+ participants in our 
sample was 16 years, with 23.6% being 12 years or younger and 53.9% being 15 years or 
younger. In children and younger adolescents, the clinical significance as well as the psychosis-
predictive value of UHR criteria, especially of APS, was reported to be significantly lower than in 
individuals aged 16 or older3-5,41. Thus, the rather high proportion of participants below 16 years 
might have lowered the overall transition rate considerably. Second, the remission rate from UHR 
status in non-converters (62.5%) was in the upper range of what is typically described42, 
suggesting that UHR symptom fluctuation is very common in this population19. Several 
characteristics of the 22q11DS, such as intellectual disability and heightened anxiety levels, and 
their impact on adaptive functioning and everyday living skills, might indicate that stress sensitivity 
significantly influences variability in symptom severity43,44. Importantly, the interplay of these factors 
in daily life will have to be examined in future studies as they carry potentially crucial clinical 
implications. 
Although the number of participants meeting criteria for each specific UHR condition (APS, 
BLIPS and GRFD) remains limited, we observed that a higher percentage of participants with 
BLIPS (100%) converted to psychosis, followed by APS (20.0%), and GRFD (16.7%). This pattern 
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falls in line with results from a recent meta-analysis reporting the highest transition risk for BLIPS, 
and the lowest for GRFD3. Yet, while our numbers were consistent with the pooled transition rate 
for APS reported in that meta-analysis (17.4% at two and 29.1% at three years), the reported 
pooled transition rates for BLIPS (46.6% at two and 51.8% at three years) and GRFD (1.9% at two 
and 1.4% at three years) were lower in that meta-analysis than those found in the present sample3. 
We found that non-perceptive APS/BLIPS were a stronger predictor of transition to psychosis 
than perceptive APS/BLIPS. This finding is in line with previous reports of a low clinical 
significance of perceptive APS in children and adolescents from the general population23,45,46. This 
highlights the need for further studies examining UHR criteria and symptoms in relation to age in 
patients with 22q11DS. 
The rate of false negative cases (i.e., UHR participants who converted to psychosis) was 
higher (4.5%) than that reported in recent meta-analyses (0.9-1.6%) on patients seeking help at 
specialized early psychosis detection services3,4. This corroborates the fact that 22q11DS is a 
psychosis-risk condition in itself and linked to a higher baseline probability to develop psychosis. It 
also highlights the need of investigating other potential risk markers (e.g., clinical or cognitive) in 
order to improve the detection of patients who will convert to psychosis. 
 
Other predictors of transition to psychosis 
 
In addition to UHR criteria, only lower baseline level of functioning, but not the presence of a 
functional deficit, significantly increased the predictive value of the model in our sample. This 
finding is in line with several studies that also identified lower functioning scores as a relevant 
predictor of the onset of psychosis in UHR41,47-49 as well as 22q11DS samples21,50. Yet, contrary to 
other findings in 22q11DS19,20, baseline verbal IQ and presence of an anxiety disorder did not 
increase the predictive value of the model. However, it should be noted that these previous studies 
never included UHR status as a baseline predictor. Hence, it is possible that including UHR status 
as a predictor reduced the variance explained by these other factors. Another potential explanation 
of this finding is that anxiety and verbal IQ decline precede or co-occur with the onset of UHR 
symptoms but do not predict transition to psychosis. Future studies examining the temporal 
dynamics of these different risk factors may help testing these hypotheses. 
 
Strengths and limitations 
 
This is the first study examining the predictive value of UHR criteria in patients with 22q11DS, 
which constitutes an important first step towards prevention of psychosis in this population. 
However, the relatively small sample size prevented a more detailed analysis of clinical outcomes 
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or of interactions between variables. This limitation should be considered in light of the low 
prevalence of the syndrome, and is generally found in all longitudinal studies on 22q11DS19.  
A second limitation is the variable interval between the two assessments, which has been 
taken into account by the use of Cox regression analyses. This also deals with the fact that the 
true survival time is unknown in such studies (i.e., some participants are still likely to develop 
psychosis after the second assessment)32.  
A third limitation is the variance in age of the participants, that might have influenced some of 
the results, although it has been reported that the mean age of onset of psychosis in 22q11DS is 
lowered7,19. Furthermore, neither our assessment nor our sample size allowed a detailed analysis 
of treatment effects. However, this neglect of treatment effects beyond the prescription of 
antipsychotics is rather the rule than the exception in naturalistic UHR follow-up studies. 
 
 
CONCLUSIONS 
 
Our findings suggest that the psychopathological path leading to transition to psychosis in 
22q11DS is broadly comparable to that observed in other clinical high risk samples, and confirm 
that 22q11DS can serve as a good human model for studying risk factors for psychosis.  
The relatively high percentage of false negative highlights that our efforts should now focus on 
investigating other possible, more subtle, risk markers - such as cognitive deficits and basic 
symptoms – to increase the sensitivity of our predictive model2. The role of low functioning as a 
predictor of transition to psychosis should also be investigated more in depth by distinguishing 
different areas of functioning. 
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Table 1  Descriptive characteristics of non-ultra high risk (UHR–) and ultra high risk (UHR+) 
participants at baseline 
 
 UHR– (N=67) UHR+ (N=22) Statistics  
Age (years), mean±SD (range) 15.9±4.9 (8-30) 16.6±4.0 (9-24) t=–0.616, p=0.539 
Gender, N females (%) 38 (56.7%) 10 (45.4%) χ2=0.845, p=0.358 
Any antipsychotics, N (%)  0 (0%) 5 (22.7%) χ2=16.134, p<0.001 
SIPS P1, median (range) 1.00 (0-3) 3.00 (0-4) U=1217.00, p<0.001 
SIPS P2, median (range) 1.00 (0-3) 2.50 (1-5) U=1174.00, p<0.001 
SIPS P3, median (range) 0.00 (0-2) 0.00 (0-3) U=857.50, p=0.145 
SIPS P4, median (range) 0.00 (0-4) 3.00 (0-6) U=1298.00, p<0.001 
SIPS P5, median (range) 0.00 (0-3) 2.00 (0-5) U=1027.00, p=0.002 
Any Axis I diagnosis, N (%)  41 (61.2%) 16 (72.7%) χ2=0.957, p=0.328 
Any anxiety disorder, N (%) 20 (29.9%) 13 (59.1) χ2=6.069, p=0.014 
Any mood disorder, N (%) 15 (22.4%) 5 (22.7%) χ2=0.001, p=0.974 
Any behavioral disorder, N (%) 17 (25.4%) 6 (27.3%) χ2=0.031, p=0.860 
Any substance use, N (%) 1 (1.5%) 0 (0%) χ2=0.332, p=0.564 
CGAS/GAF score, mean±SD 63.0±11.3 56.6±8.8 U=484.50, p=0.016 
CGAS/GAF score <70, N (%)  45 (67.2%) 19 (86.4%) χ2=3.022, p=0.082 
Verbal IQ, mean±SD 81.1±13.2 77.3±10.8 t=1.227, p=0.223 
Performance IQ, mean±SD 77.1±11.9 73.9±14.1 t=1.070, p=0.288 
Full-scale IQ, mean±SD 77.6±11.9 74.1±11.9 t=1.208, p=0.230 
CBCL/ABCL internalizing t-
score, mean±SD 
62.7±11.0 70.3±9.4 U=1036.5, p=0.004 
CBCL/ABCL externalizing t-
score, mean±SD 
53.8±9.8 60.9±10.8 U=968.5, p=0.009 
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CBCL/ABCL total problems t-
score, mean±SD 
62.1±10.7 69.5±11.5 U=998.00, p=0.013 
 
SIPS – Structured Interview for Psychosis-Risk Syndromes, CGAS – Childhood Global Assessment 
Scale, GAF – Global Assessment of Functioning, CBCL – Child Behavior Checklist, ABCL – 
Adult Behavior Checklist 
Significant differences are highlighted in bold prints  
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Table 2  Outcome at follow-up for non-ultra high risk (UHR–) and ultra high risk (UHR+) 
participants 
 
UHR– participants (N=67) 
UHR–, N (%)  60 (89.6%) 
UHR+, N (%) 4 (6%) 
Psychotic disorder, N (%) 3 (4.5%) 
UHR+ participants (N=22) 
UHR–, N (%) 10 (45.5%) 
UHR+, N (%) 6 (27.3%) 
Psychotic disorder, N (%) 6 (27.3%) 
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Table 3  Final Cox regression model 
 
Predictors β SE Wald (df) p Exp(β) 95% CI 
Any UHR criteria at 
baseline 
1.544 0.748 4.266 (1) 0.039 4.685 1.082-20.286 
Baseline CGAS/GAF –0.086 0.030 8.209 (1) 0.004 0.903 0.865-0.973 
 
UHR – ultra high risk, CGAS – Childhood Global Assessment Scale, GAF – Global Assessment of 
Functioning  
